Integrated Functional Genomics: On the road to leishmaniasis control Dormy House

综合功能基因组学：迈向利什曼病控制之路 Dormy House

• 批准号: 7408287
• 负责人: Diane McMahon Pratt
• 金额: $ 0.4万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2008-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7408287
• 关键词: Acquired Immunodeficiency Syndrome; Africa; Basic Science; Biochemistry; Cellular biology; Clinical; Clinical Immunology; Country; Disease; Drug Design; Economic Development; Endemic Diseases; Europe; Experimental Models; Future; Genetic; Genome; Genomics; HIV; Housing; Human; Immune; Immune response; India; Infection; Institutes; International; Leishmania; Leishmaniasis; Malaria; Molecular; Parasites; Parasitic Diseases; Participant; Pharmaceutical Preparations; Protozoa; Purpose; Research; Research Personnel; Research Priority; Resources; Scientist; State-of-the-Art Reviews; Translations; World Health; World Health Organization; functional genomics; neglect; symposium; vaccine development; vaccinology

The purpose of this proposal is to convene an international symposium on leishmaniasis [Integrated Genomics on the Road to Leishmaniasis Control] in September, 2007 to define future post-genomic research strategies for the development of vaccines and drugs against leishmaniasis. Leishmaniasis, a parasitic disease, is endemic in 88 resource-poor countries, with an estimated 12 million people infected world-wide. Leishmaniasis is second only to malaria amongst the parasitic protozoa in its impact on socio-economic development, with a DALY burden of 2.4 million. Increasing overlap with the spread of AIDS has resulting in HIV / Leishmania co-infections as an increasing threat, particularly in Europe, India and East Africa. The recent completion of Leishmania genome projects, advances in our ability to study immune mechanisms in experimental models and in humans, and a greater understanding of the molecular cell biology of the host-parasite interaction. Attendees will include leading international figures in experimental and clinical immunology, vaccinology, parasite molecular cell biology, biochemistry and drug design in addition to representatives from major agencies (TDR, DNDi (Drugs for Neglected Disease Institute (WHO)), One World Health); participants will include scientists from disease endemic countries (23%) and young investigators (15%). Overall, the objectives for this meeting are: 1. To bring together key scientists involved in leishmaniasis research, in a setting conducive to exploring and developing research priorities over the coming decade 2. To review the state of the art in Leishmania molecular cell biology, biochemistry, hostpathogen interactions, host genetics and immune response 3. To formulate key short and medium term objectives for basic research (experimental and clinical), with high potential for translation into new avenues for leishmaniasis control.

该提案的目的是召开一次有关利什曼病的国际研讨会 [利什曼病控制之路上的综合基因组学] 2007 年 9 月定义 未来开发疫苗和药物的后基因组研究策略 利什曼病。利什曼病是一种寄生虫病，在 88 个资源匮乏的国家流行， 全球估计有 1200 万人被感染。利什曼病仅次于 疟疾是寄生原生动物中对社会经济发展的影响， DALY负担为240万。与艾滋病传播的重叠越来越多，导致了艾滋病毒/ 利什曼原虫合并感染的威胁日益严重，特别是在欧洲、印度和东非。 最近完成的利什曼原虫基因组计划，提高了我们研究免疫的能力 实验模型和人类的机制，以及对 宿主-寄生虫相互作用的分子细胞生物学。与会者将包括领导 实验和临床免疫学、疫苗学、寄生虫分子领域的国际人物 细胞生物学、生物化学和药物设计以及主要机构的代表 （TDR、DNDi（被忽视疾病药物研究所 (WHO)）、One World Health）；参与者将 其中包括来自疾病流行国家的科学家（23%）和年轻的研究人员（15%）。 总体而言，本次会议的目标是： 1. 将参与利什曼病研究的主要科学家聚集在一起，在有利于 探索和发展未来十年的研究重点 2. 回顾利什曼原虫分子细胞生物学、生物化学、宿主病原体的最新进展 相互作用、宿主遗传学和免疫反应 3. 制定基础研究（实验和研究）的中短期重点目标 临床），具有转化为利什曼病控制新途径的巨大潜力。